Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 287-292

  Paniccia, Rita ^a,b   Antonucci, Emilia ^a,b,c   Maggini, Niccolò ^a,c   Miranda, Marco ^a   Gori, Anna Maria ^a,b,c   Marcucci, Rossella ^a,b   Giusti, Betti ^a   Balzi, Daniela ^d   Prisco, Domenico ^a,b   Abbate, Rosanna ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliero Universitaria Careggi ^*  (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d Unit of Epidemiology   (Italy)

Author keywords

Clopidogrel therapy; Light transmission aggregometry; Multiple electrode aggregometry; Point of care testing; Residual platelet reactivity

Indexed keywords

CLOPIDOGREL;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIPLE ELECTRODE PLATELET AGGREGOMETRY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG MONITORING; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 77955449383     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-12-0832     Document Type: Article

References (38)

1. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008; 100: 196-203.
2. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-1977.
3. Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787. (Pubitemid 36603418)
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
5. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-1832. (Pubitemid 41579803)
6. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425. (Pubitemid 44522148)
7. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231. (Pubitemid 47069129)
8. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity following clopidogrel adminstration on drug-eluting. J Am Coll Cardiol 2007; 49: 2312-2317. (Pubitemid 46891710)
9. Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006; 98: 1156-1159. (Pubitemid 44584095)
10. Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006; 118: 487-493. (Pubitemid 44292804)
11. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
12. Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007; 128: 143-149.
13. Harrison P, Frelinger AL 3rd, Furman MI, et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323-336.
14. Jakubowski JA, Payne CD, Li YG, et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost. 2008; 99: 409-415.
15. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
16. Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost. 2010; 103: 29-33.
17. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 2007;121: 249-258.
18. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
19. Siller-Matula JM, Gouya G, Wolzt M, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397-403.
20. Paniccia R, Antonucci E, Maggini N, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131: 834-842.
21. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
22. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
23. Buiatti E, Barchielli A, Marchionni N, et al. Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). Eur Heart J 2003; 24: 1195-1203.
24. Expert committee on the diagnosis, classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: 5-20.
25. Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-1786.
26. Ouriel K. Peripheral arterial disease . Lancet 2001; 358: 1257-1264.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
28. Tóth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
29. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
30. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-625.
31. Breugelmans J, Vertessen F, Mertens G, et al. Multiplate whole blood impedance aggregometry: a recent experience. Thromb Haemost 2008; 100: 725-726.
32. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
33. von Beckerath N, Sibbing D, Jawansky S, et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. Blood Coagulation and Fibrinolysis 2010; 21: 46-52.
34. Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008; 99: 1127-1129.
35. Kalb ML, Potura L, Scharbert G, et al. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20: 7-11.
36. Paniccia R, Antonucci E, Maggini N, et al. Platelet aggregation in whole blood: sodium citrate or hirudin as anticoagulant? [Abstract]. J Thromb Haemost 2009; 7 (Suppl 2): PP-WE-746.
37. Braun S, von Beckerath N, Ellert J, et al. Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system. Am J Clin Pathol 2009; 132: 802-803; author reply 803-804.
38. Gawaz M, Geisler T. Coronary artery disease: Platelet activity: an obstacle for successful PCI. Nat Rev Cardiol 2009; 6: 391-392.